For UK MedTech companies
Your device isn't reaching the UK private hospital sector, and that's costing you margin
The UK independent acute hospital market is now worth billions and growing. Private hospitals procure faster than the NHS and at higher margins, yet most MedTech sales teams are structured entirely around NHS pathways.
Two minutes. Solva follows up with specific private hospital channel options.
- MedTech sales teams exclusively targeting NHS trusts and procurement frameworks
- Marketing materials focused on cost-effectiveness and population health outcomes
- Limited or no engagement with private hospital clinical directors or theatre managers
- Absence from private healthcare industry events and conferences
- Inefficient resource allocation towards NHS-only sales channels
- Lack of tailored sales and marketing strategies for private providers
- Lost revenue from untapped market segments
- Reduced market share against competitors focusing on private sector
- Perception as an NHS-only supplier, limiting brand appeal to private providers
- Missed opportunities to build relationships with key private healthcare opinion leaders
The independent acute hospitals market in the UK grew by 6.9% in 2024. (LaingBuisson, 2025)
Frequently asked questions
Why does this problem persist?
UK private hospitals - HCA, Spire, Nuffield, Circle - make procurement decisions faster than the NHS and at higher margins. Many MedTech companies ignore this channel because their sales team is NHS-trained. The private sector requires a different value proposition: patient outcomes, consultant preference, and premium positioning.
What is the cost of leaving it unaddressed?
The UK independent acute hospital market, including NHS Private Patient Units, crossed £8 billion in 2024, representing a significant addressable market for MedTech companies. (LaingBuisson, 2025)
This is exactly what I do with UK private practices. Answer the few questions above and I'll come back personally with where to start. Paul.